Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis
Gerber, David E, Beg, M Shaalan, Fattah, Farjana, Frankel, Arthur E, Fatunde, Oluwatomilade, Arriaga, Yull, Dowell, Jonathan E, Bisen, Ajit, Leff, Richard D, Meek, Claudia C, Putnam, William C, Kallem, Raja Reddy, Subramaniyan, Indhumathy, Dong, Ying, Bolluyt, Joyce, Sarode, Venetia, Luo, Xin, Xie, Yang, Schwartz, Brian, Boothman, David A
Published in British journal of cancer (01.10.2018)
Published in British journal of cancer (01.10.2018)
Get full text
Journal Article
Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer
Beg, Muhammad Shaalan, Huang, Xiumei, Silvers, Molly A., Gerber, David E., Bolluyt, Joyce, Sarode, Venetia, Fattah, Farjana, Deberardinis, Ralph J., Merritt, Matthew E., Xie, Xian‐Jin, Leff, Richard, Laheru, Daniel, Boothman, David A.
Published in Journal of surgical oncology (01.07.2017)
Published in Journal of surgical oncology (01.07.2017)
Get full text
Journal Article
Phase 1 study of ARQ 761, a β-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis
Gerber, David E., Bisen, Ajit Kumar, Beg, Muhammad Shaalan, Frankel, Arthur E., Fatunde, Oluwatomilade, Fattah, Farjana, Arriaga, Yull Edwin, Dowell, Jonathan, Meek, Claudia, Bolluyt, Joyce D., Sarode, Venetia, Luo, Xin, Xie, Yang, Schwartz, Brian E., Boothman, David A., Leff, Richard
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article